Company information
Related News
- Hanmi Pharmaceutical Co., Ltd., established in 1973, is a major South Korean pharmaceutical company based in Seoul. The company focuses on the development, manufacturing, and marketing of innovative drugs, with a strong emphasis on R&D. Hanmi's key products include Amosartan for hypertension and Esomezol for acid-related diseases. In 2023, Hanmi reported revenues of approximately $1.8 billion. The company allocates a significant portion of its revenue to R&D, fostering advancements in diabetes, obesity, and cancer treatments. Hanmi collaborates with international pharmaceutical companies to enhance its research capabilities and expand its global market presence, maintaining a commitment to improving public health.
- Labscovery : platform technology that prolongs the active duration of biologics and makes it possible for once-weekly or monthly drug administration. PENTAMBODY : This platform allows the antibody to simultaneously bind two different targets for both immuno-oncology therapy and targeted therapy
- Public
- Pharma, Investor, CDMO, Bio
- CodePhase IIIEfpeglenatideObesityCodePhase IIIPoziotinibNSCLCCodePhase IIPodeltinibB-cell lymphomaCodePhase IITivumecirnonStomach cancerCodePhase IIIRisuteganibDry AMD